The women’s health and wellness space is booming. The opportunities are real and so are the rewards. This is where you keep up. Welcome to The DXF Edit.
It’s Q4, and things are back in full swing. My focus is back, and I’m getting a lot done. I haven’t committed to a formal winter arc, but I’m feeling the energy!
The backdrop is less settled. I’m watching the economy with one eyebrow raised, and Oura pausing its IPO raised the other. A company so many women love was heading to the public markets, and I wanted to see how it would play out. We’ll have to wait and see…
The rest of this edition looks past the pause. Women can now screen for cervical cancer at home, and most private insurers must cover it from 2027 for ages 30 to 65. Men are being drafted into fertility care, with new products on shelves at nearly 1,000 Ulta stores. A surrogacy court fight that began with a request to end a pregnancy made me think about situations I rarely imagine until they hit the courtrooms and the news.
MONEY MOVES
The Fertility Industry Is Really Getting Into Men
Bird&Be, a Toronto fertility brand, raised $13 million led by BDC Thrive and BFG Partners. The money is going toward something the fertility industry has spent a decade under-serving: male fertility products getting real shelf space next to female ones, now in nearly 1,000 Ulta stores nationwide.
The shelf placement says more than the funding number does. Femtech built an entire category by focusing almost exclusively on women, even though up to half of all infertility cases trace back to male factors. Fewer than 1,400 fertility specialists practice in the whole country. Treating half the biology as secondary was a business decision dressed up as medical reality.
Women going through fertility treatment consistently report higher stress and lower quality of life than their male partners do, largely because they carry the physical burden of treatment alone even when the diagnosis is shared. A 2026 study of couples in IVF found something sharper than intuition: a husband’s own optimism measurably lifted his wife’s fertility-related quality of life too. Bird&Be is getting paid to fix the part of the system that left women managing the hardest parts of this process alone.
Teal Health Raised $22 Million Ahead of the 2027 Insurance Mandate for At-Home HPV Tests
Teal Health raised a $22 million Series A led by .406 Ventures, bringing total funding to $45 million. A .406 partner tied the timing of the round to insurance coverage expanding in 2027.
That expansion traces to a January rule change. HRSA updated its cervical cancer screening guidelines to include self-collected HPV testing for the first time, after FDA approved self-collection tests in 2024 and 2025 and the American Cancer Society made the same change in December. HRSA is one of three federal bodies whose recommendations the ACA requires insurers to cover, so most private plans must cover self-collected tests with no cost sharing, follow-up testing included, by January 1, 2027.
Until then, women pay. The kit costs about $99 with insurance and $249 without, while the same screen typically costs nothing in a clinic with insurance.
The self-collection option covers average-risk women ages 30 to 65. For women 21 to 29, HRSA still recommends the in-office Pap, and nearly one-third of them have never been screened, up from 12.5% in 2005.
Oura Called Off Its Stock Market Debut, and Most of the Money Was Headed to Existing Owners
Oura, the smart ring maker, called off its stock market debut on September 29, eight days after launching it. Buyers were interested, with orders running about four times the number of shares on offer.
About three of every four shares in the sale belonged to existing owners. One early investor, Forerunner, planned to sell its entire 9.3% stake, worth about $1.2 billion at the middle of the price range. Of the roughly $533 million Oura itself would have received, about $526 million was set aside to pay taxes on stock employees would receive when the company went public. That leaves almost nothing for growth, and the company was not short on cash, having generated $328 million from its operations in nine months.
The delay looks like a disagreement over price. The sale would have valued Oura at about $13.5 billion, against about $11 billion in a private funding round last October.
72% of Oura’s members are women, and an analyst still grouped the company with Peloton, GoPro and Fitbit, companies built around a single gadget. The first public test of a company whose customers are mostly women ended in a postponement.
RESEARCH & INNOVATION
A Urine and Vaginal Swab Test Flagged 96% of Aggressive Womb Cancers in a UK Trial
Women who bleed after menopause are sent for urgent cancer checks, yet only 5 to 10% turn out to have cancer. UK researchers asked 1,864 of these women to give a urine sample and a vaginal swab before their routine hospital tests, then had specialists examine the samples for abnormal cells without knowing who had cancer. The combined test found more than 80% of cancers and 95.8% of the aggressive ones.
It misses about one in five womb cancers, which rules it out as a replacement for the hospital workup. Its value is in who can wait: a negative result was right 98.8% of the time, and the test caught 96.4% of cancers that had already spread beyond the uterus, so its misses skew toward the slower-growing end.
The same team reported that current tests are poorly calibrated for Black women, who are twice as likely to die of womb cancer as White women in the UK. The new test caught every cancer in a small group of Black women, too few to build a conclusion on. It is not available to patients, and whether it spares women invasive procedures is the question the trial left open.
Oral Menopause Hormone Therapy Is Linked to Higher Clot Risk in a Large Danish Study, and Patches Show No General Increase
Danish researchers compared tens of thousands of women aged 50 to 69 who had a blood clot, stroke or heart attack with similar women who did not, using prescription records to see who took menopause hormone therapy. Pills were linked to more clots in the legs and lungs at every dose and duration studied, while stroke and heart attack risk rose only with high-dose pills (above 1 mg of estradiol a day) taken for more than a year. Patches, gels and sprays showed no general increase in clot risk at any dose or duration.
The added risk is small. Pills meant one extra clot per 1,055 women taking them for a year, on top of a baseline of about 16 clots per 10,000 women a year without hormone therapy. Hormone therapy usually gets discussed as one drug with one risk. This study splits it by form and dose, and the answers diverge.
The study is observational, so it cannot prove cause. The authors lacked data on body weight, smoking and age at menopause, and note the results might not extend to more ethnically diverse populations. A woman weighing hot flash relief against clot risk now has a number for the pill and a reason to ask about the patch.
LAW & POLICY
A Surrogate Who Refused an Abortion Lost Custody, and Justice Kagan Declined to Step In
Alaska nurse McKenna West was carrying a baby for a California couple when an April diagnosis of a severe heart defect led them to ask her to terminate the pregnancy. She refused, moved to Texas, where abortion is banned, and asked a judge for custody, saying she could not trust the couple to provide the child’s medical care. Courts in California and Texas ruled against her, and on September 22 Justice Elena Kagan rejected her emergency request without explanation.
The record cuts against tidy hero and villain stories. The couple confirmed in Dallas hearings that they had considered abortion, and the baby’s doctor testified that they have agreed to the recommended treatment and recommended letting them take him to Los Angeles for care. West’s attorney says the couple’s public commitment to lifesaving care is the result of her fight, and that they remain under a court order to provide it.
West gave birth to the boy on August 12 and was denied the conservatorship that would have given her a say in his care. Kagan gave no reasons, so the denial sets no rule, and the next surrogate in West’s position will face the same patchwork of state surrogacy and parental rights laws.
Appeals Court Strikes Down Tennessee Law Banning “Recruiting” Minors for Out-of-State Abortions
The Sixth Circuit struck down a 2024 Tennessee law making it a crime to “recruit” a pregnant minor for an abortion illegal in Tennessee, even if she gets it where it is legal. The 2-1 ruling on September 24 found the provision unconstitutional as applied to attorney Rachel Welty and Aftyn Behn, who counsel minors, and too broad to stand at all. Chief Judge Jeffrey Sutton dissented, reading the law as not reaching their speech.
Tennessee’s lawyer conceded the law would cover recruiting a minor for an abortion in Illinois, and the court found most uses would involve abortions that are legal where they happen. Because only parents and guardians are exempt, a school counselor who tells a pregnant teenager abortion is legal in Virginia could be prosecuted, even if her mother then takes her there.
The ruling follows the Ninth Circuit’s 2024 block on Idaho’s similar “recruiting” prong, which left that law’s harboring and transporting prongs standing. For now, an adult in Tennessee can answer a pregnant teenager’s questions about legal care elsewhere without risking a mandatory 11 months and 29 days in jail under this provision.
ON THE FEED
Women Are Turning the Home Into Health Infrastructure, and the Market Has Noticed
Wellness is leaving the routine and moving into the floor plan. Sleep, air, water, movement, heat and light are being built into the house, and the walking pad, vibration plate and red light panel are the visible tip. Wellness real estate reached $876 billion in 2025 and is forecast to hit $1.8 trillion by 2030, growing about 23.5% a year since 2019, faster than any other wellness sector. 60% of consumers name health and wellness as the top reason they want certain home features, up 17% in two years, and Zillow listings mentioning wellness features are up 33%.
The real home is more basic than the feed. In a nationally representative Consumer Reports survey, the top health goals for the home were sleep (54%) and mental health (46%). People own a humidifier or dehumidifier (38%), strength equipment (35%), an air purifier (27%) and a shower or tap filter (25%). Only 10% have a sauna, hot tub, massage chair or cold plunge.
Sleep is where the gender data shows up. 49% of women versus 41% of men say they actively optimize sleep (a mattress maker’s survey), and 51% of sleep-tracker users have felt anxious about their sleep score (AASM survey, Sept 23). For her: the house is the part of her health system she fully controls, so that is where she spends.
Winter Arc 2026 Meets the Longevity Boom, and a Blood Test Is Already for Sale
The 2026 winter arc began October 1 and runs 92 days, and women are running it, including TikTok planners like one built on “quiet consistency, strength, and a 90/10 balance”. Longevity is the other wellness story of 2026, with the industry’s biggest trends report pointing to women’s healthspan as a defining shift. A 92-day challenge covers a small slice of a goal measured in decades.
The habit with the strongest case is the cheapest. A review of 57 studies linked about 7,000 steps a day to a 47% lower risk of death than 2,000 steps, with small added benefit beyond that. A common winter arc rule is 10,000 steps.
Some of the money has already found the trend. A blood-testing company’s winter arc guide tells readers to test cortisol, HbA1c, ApoB and hs-CRP on Day 0 and Day 90 and sells a $349-a-year membership, while the same guide says no controlled evidence links the trend to body-composition results. For a challenge with no outcome data, the step count that tracks with a longer life costs nothing.